GlassScriptPhysician profile
Roxana Ghashghaei
NPI 1811315674
$397,757.61
in general payments reported to CMS, 2019-2025
21 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $2,709 · 2021: $45K · 2022: $44K · 2023: $107K · 2024: $117K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $214K · Consulting Fee: $50K · Travel and Lodging: $32K · Food and Beverage: $8,653 · Education: $83.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214,432.50 |
| Consulting Fee | $49,738.49 |
| Travel and Lodging | $31,548.37 |
| Food and Beverage | $8,652.86 |
| Education | $83.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $186,494.65 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $121,857.83 | 2023-2025 | Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $62,553.25 | 2020-2025 | Amvuttra, Onpattro |
| Edwards Lifesciences Corporation | $21,875.00 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bridgebio Pharma, INC. | $2,540.04 | 2025 | Attruby |
| Medtronic, INC. | $400.00 | 2019 | |
| Vifor (International) LTD. | $393.33 | 2020 | |
| Covidien LP | $386.67 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $266.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $216.20 | 2019-2024 | |
| Abiomed | $147.15 | 2019 | |
| Novo Nordisk INC | $135.04 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $119.76 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.02 | 2019 | |
| United Therapeutics Corporation | $100.00 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $92.86 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Terumo Medical Corporation | $22.42 | 2019 | |
| Philips North America LLC | $21.80 | 2024 | (9148) Ice 3d |
| Cardiovascular Systems INC. | $17.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Ghashghaei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.